Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma

Background: This review aims to describe the systemic treatment options for pancreatic ductal adenocarcinoma and includes a summary of the current treatments as well as the ongoing clinical trials which may be efficacious in the treatment of this aggressive malignancy. Methods: A literature review was performed using MEDLINE/PubMed between August 1996 and February 2023. The reviewed studies are categorized into these categories: current standard of care treatments, targeted therapies, immunotherapy and clinical trials. The current treatment modality for the treatment of advanced pancreatic cancer is mainly systemic chemotherapy. Results: The introduction of polychemotherapy regimens including gemcitabine/nab-paclitaxel and FOLFIRINOX (oxaliplatin, irinotecan, folinic acid and fluorouracil) has improved the clinical outcome of advanced pancreatic cancer. For further improvement in clinical outcomes, several novel approaches have been extensively studied in pancreatic cancer. The review discusses the current standard chemotherapy regimen and the novel treatment options in the field. Conclusions: While there are novel treatments being explored for metastatic pancreatic, it remains a debilitating and aggressive disease with high mortality that warrants continued efforts to advance therapeutic options.

[1]  M. Frenkel,et al.  Complementary and Integrative Medicine in Pancreatic Cancer , 2023, Current Oncology Reports.

[2]  J. Berlin,et al.  Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations. , 2023, Journal of Clinical Oncology.

[3]  E. Van Cutsem,et al.  NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). , 2023, Journal of Clinical Oncology.

[4]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[5]  T. Burns,et al.  Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. , 2022, The New England journal of medicine.

[6]  R. Schulick,et al.  Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy. , 2022, JAMA oncology.

[7]  J. Neoptolemos,et al.  Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. , 2022, The lancet. Gastroenterology & hepatology.

[8]  S. Domchek,et al.  Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. , 2022, The Lancet. Oncology.

[9]  B. Fox,et al.  Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. , 2022, The New England journal of medicine.

[10]  B. Gloor,et al.  High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity. , 2022, European journal of cancer.

[11]  J. Rasko,et al.  The next wave of cellular immunotherapies in pancreatic cancer , 2022, Molecular therapy oncolytics.

[12]  Seung‐Mo Hong,et al.  Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions , 2021, Cancers.

[13]  H. Katayama,et al.  Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407). , 2021 .

[14]  K. Nathanson,et al.  Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2 , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Joon-Oh Park,et al.  Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Joon-Oh Park,et al.  Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. , 2021 .

[17]  E. Petricoin,et al.  Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  Hui Jiang,et al.  Clinical Effect of Driver Mutations of KRAS, CDKN2A/P16, TP53, and SMAD4 in Pancreatic Cancer: A Meta-Analysis. , 2020, Genetic testing and molecular biomarkers.

[19]  P. Bossuyt,et al.  Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. , 2020, JAMA oncology.

[20]  Joon-Oh Park,et al.  Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  I. Salmon,et al.  NTRK gene fusions in bilio-pancreatic cancers. , 2020 .

[22]  Namita S. Gandhi,et al.  SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). , 2020 .

[23]  E. Petricoin,et al.  Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. , 2020, The Lancet. Oncology.

[24]  S. Bates,et al.  HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). , 2020 .

[25]  A. Chen,et al.  Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Edward J. Kim,et al.  Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. , 2020, The lancet. Gastroenterology & hepatology.

[27]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Korn,et al.  Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial. , 2020, JAMA oncology.

[29]  G. Molina,et al.  Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer , 2019, Annals of Surgical Oncology.

[30]  Myung Ah Lee,et al.  Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[31]  J. Cameron,et al.  Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. , 2019, Annals of surgery.

[32]  Jeffrey W. Clark,et al.  Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. , 2019, JAMA oncology.

[33]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[34]  J. Berlin,et al.  APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. , 2019, Journal of Clinical Oncology.

[35]  M. Hidalgo,et al.  Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[37]  David Bonekamp,et al.  NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. , 2018, Cancer discovery.

[38]  Jeffrey W. Clark,et al.  Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial , 2018, JAMA oncology.

[39]  Hongxuan Tong,et al.  The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis , 2018, Scientific Reports.

[40]  Joon-Oh Park,et al.  Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC). , 2018 .

[41]  I. Voutsadakis,et al.  FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II Studies , 2018, Journal of clinical medicine.

[42]  R. Jain,et al.  Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy , 2017, Science Translational Medicine.

[43]  B. Dörken,et al.  CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  David Goldstein,et al.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.

[45]  Yan-Shen Shan,et al.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.

[46]  R. Salem,et al.  Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer , 2016, British Journal of Cancer.

[47]  J. Kench,et al.  Meta‐analysis of radical resection rates and margin assessment in pancreatic cancer , 2015, The British journal of surgery.

[48]  A. Ribas.  Releasing the Brakes on Cancer Immunotherapy. , 2015, The New England journal of medicine.

[49]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[50]  D. Hedley,et al.  Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  P. Ghiorzo.  Genetic predisposition to pancreatic cancer. , 2014, World journal of gastroenterology.

[52]  Joon-Oh Park,et al.  A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.

[53]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[54]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[55]  A. Hinke,et al.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.

[56]  R. Abrams,et al.  Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial , 2013, The Lancet. Oncology.

[57]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[58]  T. Mcclanahan,et al.  IL-10 elicits IFNγ-dependent tumor immune surveillance. , 2011, Cancer cell.

[59]  P. Bingham,et al.  Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo , 2011, Journal of Molecular Medicine.

[60]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[61]  F. McCormick,et al.  Therapeutic strategies for targeting ras proteins. , 2011, Genes & cancer.

[62]  H. Friess,et al.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.

[63]  R. Abrams,et al.  Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. , 2008, JAMA.

[64]  B. Friedenson.  BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. , 2005, MedGenMed : Medscape general medicine.

[65]  M. King,et al.  BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. , 2001, Human molecular genetics.

[66]  D. Winchester,et al.  Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. , 1999, Journal of the American College of Surgeons.

[67]  J. Kench,et al.  Hypermutation In Pancreatic Cancer. , 2017, Gastroenterology.

[68]  W. Scheithauer,et al.  nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. , 2015, Journal of the National Cancer Institute.

[69]  T. Conroy,et al.  Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.